Status:
RECRUITING
Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro
Lead Sponsor:
Oswaldo Cruz Foundation
Conditions:
Sexually Transmitted Diseases
Syphilis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if doxycycline post-exposure prophylaxis (doxy-PEP) can help prevent bacterial sexually transmitted infections (STIs) among sexual and gender minorities in ...
Eligibility Criteria
Inclusion Criteria:
- Individuals assigned male at birth (cisgender or transgender men), transgender women, or travestis who have sex with men
- Age ≥18 years
- Living with HIV or currently using HIV pre-exposure prophylaxis (PrEP) for at least 6 months
- History of at least one bacterial sexually transmitted infection (chlamydia, gonorrhea, or syphilis) in the past 12 months (laboratory-confirmed or self-reported)
- Willing and able to provide informed consent
Exclusion Criteria:
- Known allergy or hypersensitivity to doxycycline or other tetracycline-class antibiotics
- Current use of medications that may significantly interact with doxycycline or are contraindicated, including systemic retinoids, barbiturates, carbamazepine, or phenytoin
Key Trial Info
Start Date :
October 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07500415
Start Date
October 28 2025
End Date
May 1 2028
Last Update
March 30 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Infectologia Evandro Chagas
Rio de Janeiro, Rio de Janeiro, Brazil, 21040-360